EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieÄquivalenzstudie

Flecainide to Prevent Atrial Arrhythmia After Patent Foramen Ovale Closure: AFLOAT Study, A Randomized Clinical Trial

Marie Hauguel-Moreau, Paul Guedeney iD, Claire Dauphin iD, Vincent Auffret iD, Jean-Michel Clerc, Eloi Marijon iD, Meyer Elbaz iD, Philippe Aldebert, Farzin Beygui, Wissam Abi Khalil, Antoine Da Costa, Jean-Christophe Macia und 15 weitere

Circulation · 19.11.2024 · 150 (21) · 1659-1668

DOI: 10.1161/circulationaha.124.071186 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Circulation, erschienen am 19.11.2024. Verfasst von Marie Hauguel-Moreau und 26 weiteren Autor:innen. Beteiligte Einrichtung: ACTION Study Group, CESP, INSERM U1018, Department of Cardiology, Ambroise Paré Hospital (AP-HP), Université de Versailles-Saint Quentin, Boulogne, F…. Hauptthemen laut MEDLINE: Flecainide, Atrial Fibrillation, Foramen Ovale, Patent, Anti-Arrhythmia Agents. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: ACTION Study grouo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The real incidence of atrial arrhythmia (AA) after patent foramen ovale (PFO) closure and whether this complication can be prevented remain unknown. We assessed whether flecainide is effective to prevent AA during the first 3 months after PFO closure, and whether 6 months of treatment with flecainide is more effective than 3 months to prevent AA after PFO closure. METHODS: AFLOAT (Assessment of Flecainide to Lower the Patent Foramen Ovale Closure Risk of Atrial Fibrillation or Tachycardia Trial) is a prospective, multicentre, randomized, open-label, superiority trial with a blind evaluation of all the end points (PROBE [Prospective Randomized Open, Blinded End Point] design). Patients were randomized in a 1:1:1 ratio after PFO closure to receive flecainide (150 mg once daily in a sustained-release dose) for 3 months, flecainide (150 mg once daily in a sustained-release dose) for 6 months, or no additional treatment (standard of care) for 6 months. The primary end point was the percentage of patients with at least 1 episode of AA (≥30 seconds) recorded within 3 months after PFO closure on long-term monitoring with an insertable cardiac monitor. The secondary end point was the percentage of patients with at least 1 episode of AA (≥30 seconds) recorded with insertable cardiac monitor during the 3- to 6-month period after PFO closure. RESULTS: A total of 186 patients were included (mean age, 54 years; 68.8% men) and AA (≥30 seconds) occurred in 53 patients (28.5%) during the 6-month follow-up; 86.8% of these AA events occurred in the first month after PFO closure. The primary outcome occurred in 33 of 123 (26.8%) and 16 of 63 (25.4%) patients receiving flecainide for at least 3 months or standard of care, respectively (risk difference, 1.4% [95% CI, −12.9% to 13.8%]; NS). The secondary end point occurred in 3 of 60 (5.0%), 4 of 63 (6.3%), and 5 of 63 (7.9%) patients receiving flecainide for 6 months, for 3 months, or standard of care, respectively (risk difference, −2.9% [95% CI, −12.7% to 6.9%], and risk difference, −1.6% [95% CI, −11.8% to 8.6%], respectively). CONCLUSIONS: In the first 6 months after successful PFO closure, AA (≥30 seconds) occurred in 28.5% of cases, mostly in the first month after the procedure. Flecainide did not prevent AA after PFO closure. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05213104.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FlecainideAtrial FibrillationForamen Ovale, PatentAnti-Arrhythmia AgentsHumansMaleFemaleMiddle AgedProspective StudiesAgedAdultTreatment Outcome

Stichwörter der Autor:innen

atrial fibrillationflecainideforamen ovale, patentrandomized controlled trial

Substanzen

FlecainideAnti-Arrhythmia Agents

Autor:innen und Institutionen

  • ACTION Study Group, CESP, INSERM U1018, Department of Cardiology, Ambroise Paré Hospital (AP-HP), Université de Versailles-Saint Quentin, Boulogne, France (M.H.-M.).
  • ACTION Study Group, INSERM UMRS1166, ICAN-Institute of Cardiometabolism and Nutrition, Sorbonne Université (P.G., M.L., T.R., Y.T., M.E.G., D.B., J.S., N.H., G.D., G.M.), Institut de Cardiologie, Hôpital Pitié-Salpêtriè…
  • Department of Cardiology and Cardiovascular Diseases, Clermont-Ferrand University Hospital, France (C.D.).
  • Department of Cardiology, INSERM LTSI U1099, Rennes University Hospital, University of Rennes, France (V.A.).
  • Cardiology Department, Centre Hospitalier Universitaire de Tours, France (J.-M.C.).
  • Cardiology Department, European Georges Pompidou Hospital, Paris, France (E.M.).

ORCID-Profile: Paul Guedeney, Claire Dauphin, Vincent Auffret, Eloi Marijon, Meyer Elbaz, Simon Elhadad, Guillaume Cayla, Xavier Iriart, Mikael Laredo, Thomas Rolland, Maria Elisabeta Gheorghiu, Johanne Silvain, Nadjib Hammoudi, Guillaume Duthoit, Abdourahmane Diallo, Gilles Montalescot

Förderung

  • ACTION Study grouo

Zitieren

APA

Hauguel-Moreau, M., Guedeney, P., Dauphin, C., Auffret, V., Clerc, J. M., Marijon, E., Elbaz, M., Aldebert, P., Beygui, F., Abi Khalil, W., Da Costa, A., Macia, J. C., Elhadad, S., Cayla, G., Iriart, X., Laredo, M., Rolland, T., Temmar, Y., Gheorghiu, M. E., …, & ACTION Study Group (2024). Flecainide to Prevent Atrial Arrhythmia After Patent Foramen Ovale Closure: AFLOAT Study, A Randomized Clinical Trial. Circulation, 150(21), 1659-1668. https://doi.org/10.1161/circulationaha.124.071186

Vancouver

Hauguel-Moreau M, Guedeney P, Dauphin C, Auffret V, Clerc JM, Marijon E, et al. Flecainide to Prevent Atrial Arrhythmia After Patent Foramen Ovale Closure: AFLOAT Study, A Randomized Clinical Trial. Circulation. 2024;150(21):1659-1668. doi:10.1161/circulationaha.124.071186

BibTeX
@article{HauguelMoreau2024,
  author = {Hauguel-Moreau, Marie and Guedeney, Paul and Dauphin, Claire and Auffret, Vincent and Clerc, Jean-Michel and Marijon, Eloi and Elbaz, Meyer and Aldebert, Philippe and Beygui, Farzin and Abi Khalil, Wissam and Da Costa, Antoine and Macia, Jean-Christophe and Elhadad, Simon and Cayla, Guillaume and Iriart, Xavier and Laredo, Mikael and Rolland, Thomas and Temmar, Yassine and Gheorghiu, Maria Elisabeta and Brugier, Delphine and Silvain, Johanne and Hammoudi, Nadjib and Duthoit, Guillaume and Diallo, Abdourahmane and Vicaut, Eric and Montalescot, Gilles and ACTION Study Group, ACTION Study Group},
  title = {Flecainide to Prevent Atrial Arrhythmia After Patent Foramen Ovale Closure: AFLOAT Study, A Randomized Clinical Trial},
  journal = {Circulation},
  year = {2024},
  volume = {150},
  number = {21},
  pages = {1659--1668},
  doi = {10.1161/circulationaha.124.071186}
}
Kostenlos starten →